- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06264557
Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment (SB-DEX)
A Multicenter, Prospective, Comparative, Randomized, Independent Rater-blind, Superiority Clinical Trial to Compare the Safety and Efficacy of the Cognitive Therapy Software 'SUPERBRAIN DEX' With a Control Group for Patients With MCI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hyunsung Yoon
- Phone Number: 010-5544-0970
- Email: yswon111@rowan.kr
Study Contact Backup
- Name: Yeji Hwang
- Phone Number: 010-6697-2739
- Email: yjss1305@rowan.kr
Study Locations
-
-
-
Busan, Korea, Republic of
- Recruiting
- Inje University Haeundae Paik Hospital
-
Contact:
- Jinse Park, PI
-
Incheon, Korea, Republic of, 22332
- Recruiting
- Inha University Hospital
-
Contact:
- Hyewon Yoon, PI
-
Incheon, Korea, Republic of
- Recruiting
- Gachon University Gil Medical Center
-
Contact:
- Kee Hyung Park, PI
-
Kwangju, Korea, Republic of
- Recruiting
- Chonnam National University Hospital
-
Contact:
- Soo Hyun Cho, PI
-
Seoul, Korea, Republic of
- Recruiting
- Korea University Anam Hospital
-
Contact:
- Chan Nyoung Leee, PI
-
Seoul, Korea, Republic of
- Recruiting
- Hanyang University Seoul Hospital
-
Contact:
- Jin Seok Park, PI
-
Seoul, Korea, Republic of
- Recruiting
- Koera University Guro Hospital
-
Contact:
- Chi Kyung Kim, PI
-
Seoul, Korea, Republic of
- Recruiting
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Contact:
- Dong Woo Kang, PI
-
Seoul, Korea, Republic of
- Recruiting
- Ewha Womans University Seoul Hospital
-
Contact:
- Ji Young Yun, PI
-
Suwon, Korea, Republic of
- Recruiting
- The Catholic University of Korea, St. Vincent's Hospital
-
Contact:
- Yoo Hyun Um, PI
-
Suwon, Korea, Republic of
- Recruiting
- Ajou University Hospital
-
Contact:
- Sun Min Lee, PI
-
-
Gyeonggi-do
-
Guri-si, Gyeonggi-do, Korea, Republic of, 11923
- Recruiting
- Hanyang University Guri Hospital
-
Contact:
- Hojin Choi, PI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 50 - 85years old
Those who meet all of the National Institute on Aging-Alzheimer's Association (NIA-AA) key clinical criteria below that may suspect mild cognitive impairment caused by Alzheimer's disease as of the screening date
- Concern of the subject or guardian about the deterioration of cognitive function compared to before
- More than one cognitive impairment
- Maintaining the independence of overall daily life functions
- It's not dementia
In at least one of the following neuropsychological tests conducted within one year of the screening date, the delayed recall score in the memory area was 'average -1' according to the standard score table corrected for education level and age.
- Seoul Neuropsychological Screening Battery 2nd edition (SNSB-II)
- Korean version of Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K)
- Literacy Independent Cognitive Assessment (LICA)
- A person whose Korea-Mini Mental State Examination-2 (K-MMSE-2) score corresponds to "Average-1.5 standard deviation or higher" according to the standard score table corrected for education level and age as of the screening date
- Those with a Global Clinical Dementia Rating (CDR) score of 0.5 and a memory item score of 0.5 or 1 as of the screening date
A person who has a guardian in regular contact with the subject
- Defined to be able to support subjects during the clinical trial (compliance supervision and subject status reporting) and spend at least 8 hours per week with subjects
- A person who is taking drugs (donepezil, galantamine, ribastigmine, memantine) for the purpose of improving cognitive function is taking drugs stably for at least 12 weeks as of the screening date
- Those who have no difficulty using tablet PCs
- A person who voluntarily decides to participate in this clinical trial and agrees to the subject's explanation and consent in writing
- Those who are willing to comply with the clinical trial plan
Exclusion Criteria:
- Those diagnosed with dementia (including Alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., Human Immunodeficiency Virus (HIV), syphilis, etc.), Creutzfeld-Jacob disease (Creutzfeld-Jacob disease), Pick disease, Huntington's disease, Parkinson's disease, etc.) as of the screening date
- Those who have a history of diagnosing significant neurological diseases affecting cognitive function within one year of the screening date (e.g., stroke, multiple sclerosis, severe head trauma with loss of consciousness, normal cerebral hydrocephalus, epilepsy, brain tumors, cerebral infarction, spinal cord infarction or central nervous system infection)
- Based on the screening date, major depressive disorder, bipolar disorder, schizophrenia, A person diagnosed with a serious mental illness such as drug addiction and alcoholism
Laboratory and/or vital signs tests as of the date of screening, any of the following
- Those diagnosed with infectious or metabolic diseases that may cause cognitive decline in the subject (e.g., hypothyroidism, vitamin B12 deficiency, folate deficiency, neurotoxin, HIV)
- Those with liver dysfunction (AST, ALT ≥ 3x upper limit of normal range) and/or renal dysfunction (serum creatinine ≥ 2x upper limit of normal range)
- Those with uncontrolled hypertension (SBP > 180 mmHg) and/or diabetes (HbA1c > 11%)
- Those who have severe or unstable cardiovascular disease (e.g., myocardial infarction, unstable angina, class III or IV heart failure by classification of the New York Heart Association (NYHA) within 24 weeks of the screening date)
- Where the tester determines that he/she has a medical condition that may interfere with the completion of the clinical trial due to a serious or unstable physical condition (e.g., a history of malignant tumors within five years of the screening date (e.g., basal cell cancer and squamous cell carcinoma of the skin considered to have been completely resected and cured, cervical intraepithelial carcinoma, non-transparent prostate cancer, acute and severe asthma, active peptic ulcers, etc.)
- If you can't walk, A person who can move using walking aids (e.g. walkers, canes, wheelchairs, etc.)
- an illiterate patient who is unschooled (defined as unadmitted to a regular school)
- Where the tester determines that a person does not have sufficient vision, hearing, language skills, motor skills, and comprehension to follow the examination procedures related to clinical trials
- a person who is pregnant or nursing
For women of childbearing age, who do not agree with the medically permitted contraceptive method during the clinical trial
- Hormonal contraception, intrauterine device (IUD) or intrauterine system (IUS), oviduct ligation, double blocking (male condom, female condom, cervical cap, a combination of contraceptive septum, contraceptive sponge-like blocking methods), a single blocking method with a combination of an alveolar agent
- Those who are currently participating in other clinical trials or who have participated in other clinical trials within 90 days of screening
- Other, ethical or clinical trial outcomes may be impacted and deemed inappropriate by the tester
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
Device : SB-100 Cognitive training will be conducted once a day, and it will take 15 to 30 minutes. It consists of cognitive training and educational videos. |
Cognitive training will be conducted once a day, and it will take 15 to 30 minutes. It consists of cognitive training and educational videos. |
Other: Contol group
Educational book : book of education on daily rules for preventing dementia
|
Book of education on daily rules for preventing dementia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
K-RBANS
Time Frame: Baseline, 16 weeks after treatment
|
The closer the total score of 160 points, the worse the cognitive state is, and the closer it is to 40, the worse the cognitive state is
|
Baseline, 16 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
K-RBANS
Time Frame: Baseline, 8 weeks after treatment
|
The closer the total score of 160 points, the worse the cognitive state is, and the closer it is to 40, the worse the cognitive state is
|
Baseline, 8 weeks after treatment
|
K-MMSE-2
Time Frame: Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
Total scores range from 0 to 30, with lower scores indicating more worsening.
|
Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
CDR-SB
Time Frame: Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
The closer to CDR 0 grade, the more normal the cognitive state, and the closer to CDR 3 grade, the worse the cognitive state.
|
Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
K-IADL
Time Frame: Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
It consists of a total of 11 items (0-3 points), and the score is calculated by dividing the total score by the number of corresponding items, and the closer it is to 3, the worse the cognitive state is.
|
Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
PRMQ
Time Frame: Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
The closer to the lowest 16 points, the normal memory ability, and the closer to the total score of 80 points, the worse the memory ability.
|
Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
GDS-15
Time Frame: Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
The closer it is to 0, the less depressed it is, and the closer it is to the total score of 15, the more depressed it is.
|
Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
QOL-AD
Time Frame: Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
The closer the total score of 52 points, the higher the quality of life, and the closer the minimum score of 13 points, the lower the quality of life.
|
Baseline, 8 weeks after treatment, and 16 weeks after treatment
|
ADAS-Cog14
Time Frame: Baseline, 16 weeks after treatment
|
Total scores range from 0 to 90, with higher scores indicating more worsening.
|
Baseline, 16 weeks after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RW-MCI-01
- ROWAN (Other Identifier: ROWAN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)Active, not recruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on SB-100
-
GlaxoSmithKlineCompletedOsteoporosisUnited States
-
University of MinnesotaRecruitingCardiovascular Diseases | Type 2 DiabetesUnited States
-
GlaxoSmithKlineCompletedSchizophreniaUnited Kingdom
-
Sangamo TherapeuticsActive, not recruitingHemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis IIUnited States
-
Medica Cor Heart HospitalUnknownCoronary Ostium Stenosis | MyonecrosisBulgaria
-
Nguyen Thi Trieu, MDCompletedCirrhosis of the LiverVietnam
-
GlaxoSmithKlineCompletedAtherosclerosisNetherlands, Belgium, Germany, Czechia, France, Austria, Spain, Norway, Poland, Denmark, Switzerland
-
GlaxoSmithKlineCompletedChronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, IdiopathicJapan
-
Boston Medical CenterNational Institute of Mental Health (NIMH)Completed
-
Case Comprehensive Cancer CenterActive, not recruitingAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditionsUnited States